Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rotavirus Infections | 37 | 2024 | 359 | 6.370 |
Why?
|
| Gastroenteritis | 35 | 2025 | 365 | 5.300 |
Why?
|
| Caliciviridae Infections | 31 | 2025 | 360 | 5.190 |
Why?
|
| Norovirus | 32 | 2025 | 349 | 4.750 |
Why?
|
| Rotavirus | 35 | 2024 | 505 | 4.350 |
Why?
|
| Organoids | 17 | 2025 | 299 | 4.060 |
Why?
|
| Intestinal Mucosa | 10 | 2025 | 796 | 2.000 |
Why?
|
| Virus Replication | 16 | 2025 | 635 | 1.880 |
Why?
|
| Milk, Human | 7 | 2025 | 308 | 1.840 |
Why?
|
| Oligosaccharides | 3 | 2018 | 77 | 1.640 |
Why?
|
| Blood Group Antigens | 8 | 2025 | 77 | 1.580 |
Why?
|
| Polysaccharides | 9 | 2021 | 148 | 1.550 |
Why?
|
| Viral Vaccines | 8 | 2025 | 343 | 1.490 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2024 | 810 | 1.410 |
Why?
|
| Antibodies, Viral | 13 | 2024 | 1204 | 1.380 |
Why?
|
| Rotavirus Vaccines | 8 | 2024 | 73 | 1.260 |
Why?
|
| Cell Culture Techniques | 6 | 2021 | 287 | 1.220 |
Why?
|
| Viruses | 5 | 2023 | 126 | 1.150 |
Why?
|
| Antiviral Agents | 6 | 2025 | 822 | 1.090 |
Why?
|
| Capsid Proteins | 10 | 2014 | 195 | 1.050 |
Why?
|
| Immunoglobulin A | 6 | 2016 | 218 | 1.000 |
Why?
|
| Vaccines, Virus-Like Particle | 3 | 2024 | 34 | 0.990 |
Why?
|
| India | 26 | 2021 | 237 | 0.960 |
Why?
|
| Trisaccharides | 1 | 2025 | 8 | 0.910 |
Why?
|
| Diarrhea | 12 | 2018 | 329 | 0.890 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 67 | 0.860 |
Why?
|
| Intestines | 8 | 2024 | 606 | 0.860 |
Why?
|
| Genotype | 22 | 2025 | 2703 | 0.860 |
Why?
|
| Epithelial Cells | 5 | 2021 | 903 | 0.840 |
Why?
|
| Feces | 19 | 2024 | 753 | 0.740 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2018 | 180 | 0.710 |
Why?
|
| Virus Physiological Phenomena | 2 | 2018 | 15 | 0.700 |
Why?
|
| Viral Proteins | 7 | 2025 | 357 | 0.700 |
Why?
|
| Antigens, Viral | 9 | 2020 | 439 | 0.690 |
Why?
|
| Infant, Newborn | 25 | 2024 | 8535 | 0.670 |
Why?
|
| Stem Cells | 6 | 2021 | 732 | 0.670 |
Why?
|
| Host-Pathogen Interactions | 6 | 2025 | 263 | 0.660 |
Why?
|
| Humans | 89 | 2025 | 131930 | 0.620 |
Why?
|
| Nurseries, Hospital | 2 | 2008 | 7 | 0.590 |
Why?
|
| Enterovirus | 1 | 2019 | 52 | 0.580 |
Why?
|
| Enterovirus Infections | 1 | 2019 | 49 | 0.580 |
Why?
|
| Viral Nonstructural Proteins | 6 | 2018 | 195 | 0.580 |
Why?
|
| Norwalk virus | 3 | 2024 | 170 | 0.570 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 292 | 0.560 |
Why?
|
| RNA, Viral | 7 | 2012 | 565 | 0.520 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 14 | 0.520 |
Why?
|
| Milk | 1 | 2017 | 108 | 0.510 |
Why?
|
| Genome, Viral | 2 | 2025 | 179 | 0.510 |
Why?
|
| Virus Diseases | 2 | 2021 | 289 | 0.500 |
Why?
|
| Immunoglobulin G | 6 | 2019 | 803 | 0.470 |
Why?
|
| Receptors, Virus | 5 | 2018 | 110 | 0.470 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 543 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 3 | 2024 | 500 | 0.460 |
Why?
|
| Reassortant Viruses | 2 | 2015 | 34 | 0.430 |
Why?
|
| RNA-Binding Proteins | 3 | 2018 | 604 | 0.420 |
Why?
|
| Infant | 21 | 2024 | 13032 | 0.380 |
Why?
|
| Hospitalization | 7 | 2024 | 1892 | 0.370 |
Why?
|
| Viral Load | 2 | 2010 | 408 | 0.360 |
Why?
|
| Virus Shedding | 2 | 2013 | 82 | 0.360 |
Why?
|
| Asymptomatic Infections | 1 | 2010 | 38 | 0.340 |
Why?
|
| Virus Cultivation | 3 | 2024 | 76 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2020 | 1285 | 0.320 |
Why?
|
| Viremia | 1 | 2010 | 133 | 0.320 |
Why?
|
| Infant, Premature | 3 | 2024 | 842 | 0.300 |
Why?
|
| Transcriptome | 4 | 2024 | 1122 | 0.300 |
Why?
|
| Caliciviridae | 2 | 2025 | 25 | 0.300 |
Why?
|
| Cost of Illness | 2 | 2009 | 275 | 0.300 |
Why?
|
| Diarrhea, Infantile | 1 | 2008 | 35 | 0.290 |
Why?
|
| Intestine, Small | 2 | 2021 | 309 | 0.290 |
Why?
|
| Cross Infection | 2 | 2008 | 343 | 0.280 |
Why?
|
| Phylogeny | 5 | 2025 | 762 | 0.270 |
Why?
|
| Culture Media | 3 | 2024 | 182 | 0.270 |
Why?
|
| Animals | 19 | 2025 | 34908 | 0.260 |
Why?
|
| Protease Inhibitors | 2 | 2025 | 97 | 0.260 |
Why?
|
| Poverty Areas | 1 | 2006 | 32 | 0.260 |
Why?
|
| Geographic Information Systems | 1 | 2006 | 42 | 0.260 |
Why?
|
| Vaccines | 2 | 2025 | 381 | 0.260 |
Why?
|
| Gastrointestinal Tract | 3 | 2021 | 232 | 0.250 |
Why?
|
| Mothers | 2 | 2013 | 372 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 2 | 2021 | 355 | 0.250 |
Why?
|
| Infant, Premature, Diseases | 1 | 2008 | 252 | 0.240 |
Why?
|
| Enterocytes | 2 | 2024 | 75 | 0.240 |
Why?
|
| Cricetulus | 2 | 2018 | 93 | 0.240 |
Why?
|
| CHO Cells | 2 | 2018 | 158 | 0.240 |
Why?
|
| Adult | 13 | 2025 | 31506 | 0.240 |
Why?
|
| Fucosyltransferases | 3 | 2021 | 30 | 0.240 |
Why?
|
| Cricetinae | 2 | 2018 | 381 | 0.230 |
Why?
|
| Urban Population | 1 | 2006 | 245 | 0.230 |
Why?
|
| Drug Discovery | 2 | 2023 | 174 | 0.220 |
Why?
|
| Cryptosporidium | 2 | 2020 | 34 | 0.220 |
Why?
|
| Phagocytosis | 1 | 2025 | 191 | 0.220 |
Why?
|
| Species Specificity | 5 | 2017 | 542 | 0.210 |
Why?
|
| Antibodies, Blocking | 2 | 2024 | 63 | 0.210 |
Why?
|
| Lentivirus | 1 | 2024 | 82 | 0.210 |
Why?
|
| Cell Line | 5 | 2025 | 2724 | 0.210 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2024 | 107 | 0.210 |
Why?
|
| Jejunum | 1 | 2024 | 131 | 0.210 |
Why?
|
| Protein Structure, Tertiary | 3 | 2014 | 763 | 0.210 |
Why?
|
| Cattle | 4 | 2015 | 569 | 0.200 |
Why?
|
| Child, Preschool | 16 | 2024 | 14715 | 0.200 |
Why?
|
| Gene Knockdown Techniques | 1 | 2024 | 397 | 0.200 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2025 | 233 | 0.190 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2024 | 176 | 0.190 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 689 | 0.180 |
Why?
|
| Blotting, Western | 1 | 2024 | 1080 | 0.180 |
Why?
|
| Virus Attachment | 3 | 2021 | 41 | 0.180 |
Why?
|
| Flow Cytometry | 1 | 2024 | 802 | 0.180 |
Why?
|
| Cell Survival | 1 | 2024 | 869 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2024 | 413 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2025 | 377 | 0.180 |
Why?
|
| Acute Disease | 4 | 2024 | 1161 | 0.170 |
Why?
|
| Macrophages | 1 | 2025 | 692 | 0.170 |
Why?
|
| Male | 21 | 2024 | 64846 | 0.170 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 143 | 0.170 |
Why?
|
| Female | 20 | 2024 | 70607 | 0.170 |
Why?
|
| Vaccination | 3 | 2024 | 1017 | 0.160 |
Why?
|
| Calcium | 1 | 2025 | 1078 | 0.160 |
Why?
|
| Ceramides | 1 | 2020 | 46 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2020 | 60 | 0.160 |
Why?
|
| Interferons | 1 | 2020 | 142 | 0.160 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2019 | 3 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2021 | 5143 | 0.150 |
Why?
|
| Seroepidemiologic Studies | 2 | 2016 | 144 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 5 | 2021 | 1552 | 0.150 |
Why?
|
| Colon | 1 | 2021 | 370 | 0.150 |
Why?
|
| Interdisciplinary Research | 1 | 2018 | 10 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2020 | 168 | 0.140 |
Why?
|
| Tissue Culture Techniques | 1 | 2018 | 68 | 0.140 |
Why?
|
| Glycomics | 2 | 2014 | 16 | 0.140 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 157 | 0.140 |
Why?
|
| Breast Feeding | 2 | 2018 | 233 | 0.140 |
Why?
|
| Protein Binding | 3 | 2021 | 1731 | 0.140 |
Why?
|
| Bile Acids and Salts | 1 | 2020 | 255 | 0.130 |
Why?
|
| Organ Specificity | 1 | 2018 | 412 | 0.130 |
Why?
|
| Neutralization Tests | 3 | 2024 | 237 | 0.130 |
Why?
|
| Staining and Labeling | 2 | 2014 | 182 | 0.130 |
Why?
|
| N-Acetylneuraminic Acid | 2 | 2014 | 28 | 0.130 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 196 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 3082 | 0.130 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1963 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1288 | 0.120 |
Why?
|
| Cattle Diseases | 1 | 2015 | 22 | 0.120 |
Why?
|
| Gene Expression | 1 | 2019 | 1563 | 0.110 |
Why?
|
| Protein Conformation | 3 | 2021 | 825 | 0.110 |
Why?
|
| Carbohydrate Sequence | 1 | 2014 | 18 | 0.110 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2014 | 60 | 0.110 |
Why?
|
| Saliva | 1 | 2015 | 133 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2010 | 3771 | 0.100 |
Why?
|
| Hemagglutination Tests | 1 | 2013 | 11 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 356 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1035 | 0.100 |
Why?
|
| Models, Molecular | 3 | 2021 | 1118 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 5 | 2010 | 1802 | 0.100 |
Why?
|
| Travel | 1 | 2014 | 123 | 0.100 |
Why?
|
| Binding Sites | 3 | 2021 | 1255 | 0.100 |
Why?
|
| Catalytic Domain | 2 | 2025 | 179 | 0.100 |
Why?
|
| Coculture Techniques | 2 | 2025 | 238 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2024 | 3415 | 0.090 |
Why?
|
| Genes, Viral | 2 | 2008 | 181 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 36 | 0.080 |
Why?
|
| Prevalence | 5 | 2020 | 2656 | 0.080 |
Why?
|
| Bifidobacterium | 1 | 2010 | 68 | 0.080 |
Why?
|
| Biodiversity | 1 | 2010 | 87 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2025 | 699 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2020 | 249 | 0.080 |
Why?
|
| Sequence Homology | 1 | 2009 | 63 | 0.080 |
Why?
|
| Young Adult | 5 | 2024 | 9929 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 826 | 0.070 |
Why?
|
| Beds | 1 | 2008 | 9 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2007 | 245 | 0.070 |
Why?
|
| Child | 3 | 2025 | 25756 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2019 | 387 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 303 | 0.070 |
Why?
|
| Cryptosporidiosis | 1 | 2006 | 44 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5394 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2025 | 89 | 0.060 |
Why?
|
| Hospitals | 1 | 2008 | 437 | 0.060 |
Why?
|
| Crystallography | 1 | 2025 | 39 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 138 | 0.060 |
Why?
|
| Geography, Medical | 1 | 2025 | 18 | 0.060 |
Why?
|
| Seasons | 1 | 2006 | 328 | 0.060 |
Why?
|
| Molecular Conformation | 1 | 2025 | 107 | 0.060 |
Why?
|
| Proteobacteria | 1 | 2024 | 16 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2006 | 415 | 0.050 |
Why?
|
| Food, Fortified | 1 | 2024 | 62 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2020 | 3044 | 0.050 |
Why?
|
| Calcium Signaling | 1 | 2025 | 254 | 0.050 |
Why?
|
| Mice | 4 | 2024 | 18534 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2141 | 0.050 |
Why?
|
| Biological Assay | 1 | 2023 | 111 | 0.050 |
Why?
|
| Middle Aged | 5 | 2024 | 28893 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 1350 | 0.050 |
Why?
|
| Reference Standards | 1 | 2023 | 241 | 0.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2024 | 168 | 0.050 |
Why?
|
| Polyproteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Glycoconjugates | 1 | 2021 | 8 | 0.050 |
Why?
|
| Calcitriol | 1 | 2021 | 65 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2021 | 92 | 0.040 |
Why?
|
| Laminin | 1 | 2021 | 72 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 143 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 49 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 280 | 0.040 |
Why?
|
| Zoonoses | 2 | 2013 | 52 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 260 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2024 | 6526 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 103 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 110 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 439 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2024 | 926 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 107 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 238 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 6435 | 0.040 |
Why?
|
| Oocysts | 1 | 2020 | 4 | 0.040 |
Why?
|
| Sporozoites | 1 | 2020 | 4 | 0.040 |
Why?
|
| Glycochenodeoxycholic Acid | 1 | 2020 | 8 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 309 | 0.040 |
Why?
|
| United States | 3 | 2024 | 11619 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2020 | 65 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2020 | 43 | 0.040 |
Why?
|
| Adsorption | 1 | 2019 | 36 | 0.040 |
Why?
|
| Haplorhini | 1 | 2019 | 117 | 0.040 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 192 | 0.040 |
Why?
|
| Myofibroblasts | 1 | 2020 | 64 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 136 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 152 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 94 | 0.040 |
Why?
|
| Cytokines | 1 | 2025 | 1365 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 79 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 134 | 0.040 |
Why?
|
| Histocompatibility Antigens | 1 | 2018 | 18 | 0.040 |
Why?
|
| Chile | 1 | 2018 | 25 | 0.040 |
Why?
|
| Fucose | 1 | 2018 | 22 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2021 | 290 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 205 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 402 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 293 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2018 | 296 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 3358 | 0.030 |
Why?
|
| Genomics | 1 | 2025 | 1652 | 0.030 |
Why?
|
| Toxins, Biological | 2 | 2007 | 72 | 0.030 |
Why?
|
| Bile | 1 | 2016 | 46 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2016 | 34 | 0.030 |
Why?
|
| Antibodies | 1 | 2017 | 366 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 995 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1422 | 0.030 |
Why?
|
| Developing Countries | 1 | 2017 | 276 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 1441 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2007 | 377 | 0.030 |
Why?
|
| Kobuvirus | 1 | 2014 | 2 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 2670 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2014 | 176 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4688 | 0.030 |
Why?
|
| HIV Infections | 1 | 2006 | 2048 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 130 | 0.030 |
Why?
|
| Mexico | 1 | 2014 | 185 | 0.030 |
Why?
|
| Immunoassay | 1 | 2014 | 135 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2014 | 169 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 235 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2438 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 329 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 2897 | 0.020 |
Why?
|
| Denaturing Gradient Gel Electrophoresis | 1 | 2010 | 1 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 57 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1540 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1653 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 438 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 636 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 77 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1493 | 0.020 |
Why?
|
| Cats | 1 | 2007 | 118 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 1451 | 0.020 |
Why?
|
| Sapovirus | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2007 | 24 | 0.020 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2007 | 82 | 0.020 |
Why?
|
| Carrier State | 1 | 2007 | 77 | 0.020 |
Why?
|
| Dogs | 1 | 2007 | 651 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 407 | 0.020 |
Why?
|
| DNA, Protozoan | 1 | 2006 | 32 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2006 | 140 | 0.020 |
Why?
|
| Protozoan Proteins | 1 | 2006 | 134 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 6245 | 0.010 |
Why?
|
| Virulence | 1 | 2004 | 279 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 490 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 20524 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 10893 | 0.010 |
Why?
|
| Age Factors | 1 | 2006 | 2920 | 0.010 |
Why?
|